UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Nov

    14

    New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

    May

    06

    Evolving Expectations for Arthritis Management

    Nov

    09

    Advancing Rheumatic Disease Treatment

    Jan

    18

    Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

    Nov

    10

    Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

    Nov

    09

    Moving the Conversation Forward in Rheumatology – UCB at ACR Convergence 2022

    May

    23

    First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

    May

    12

    Recognizing the Less Common, but Equally Burdensome, Forms of Arthritis During Arthritis Awareness Month

    May

    25

    UCB Statement on Non-Radiographic Axial Spondyloarthritis ICD-10 Sub-Category Update

    Today, UCB issued the following statement from Jeffrey Stark, M.D., Head of U.S. Medical Immunology, on the recent update by the ICD-10 Coordination and Maintenance Committee to endorse the creation of a new sub-category (M45.A) for non-radiographic axial spondyloarthritis (nr-axSpA). 

    May

    05

    Recognizing the Many Forms of Arthritis this Arthritis Awareness Month

    UCB is passionate about transforming the lives of people living with severe diseases and uncovering the intersections of scientific understanding and patient needs. This May, we are honoring Arthritis Awareness Month and Spondyloarthritis Awareness Month by exploring the impacts of different kinds of arthritis on patients. Learn more about psoriatic arthritis, rheumatoid arthritis, and non-radiographic axial spondyloarthritis, their prevalence, and how individuals living with these diseases are impacted.